Alterity Therapeutics Issues 3 Million Options to Executives, Confirming Dilution
ATHE sits 58% above its 52-week low of $2.66.
Summary
Alterity Therapeutics has issued 3 million options to its executives, finalizing a previously approved compensation plan that could lead to significant dilution for existing shareholders.
Key Events · Financing and Capital Events · ATHE
-
Issuance of Executive Options
Alterity Therapeutics issued 3,000,000 unquoted options to its Chairman and another executive.
-
Shareholder Approval Confirmed
The issuance follows shareholder approval received at a General Meeting on May 29, 2026, as part of a previously announced compensation plan.
-
Potential Dilution
These options represent a potential dilution of approximately 1.38% of the company's outstanding shares if exercised.
-
In-the-Money Compensation
The options have an exercise price of A$1.00 (approximately $0.66 USD) and were issued for nil consideration, making them valuable to recipients given the current stock price of $4.21.
Analysis · ATHE · Life Sciences
This filing confirms the issuance of 3 million unquoted options to executives, previously approved by shareholders. While a form of compensation, these options represent a significant potential dilution of approximately 1.38% of outstanding shares. With an exercise price of A$1.00 (approximately $0.66 USD) compared to the current stock price of $4.21, these options are deeply in-the-money, making them a valuable incentive for the recipients but potentially dilutive for existing shareholders upon exercise.
How filings like this one have moved
In the 30 days to Oct 22, 2026, 36.9% of the 1029 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.77%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ATHE was trading at $4.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $75.8M. The 52-week trading range was $2.66 to $7.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.